A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The aim of this review is to summarize the clinical efficacy, tolerability and safety data of insulin detemir, and compare its use with that of neutral protamine Hagedorn (NPH) insulin in randomized controlled trials in people with type 1 or type 2 diabetes. A literature search was conducted with PubMed using predefined search terms. Studies were included if they met the following criteria: randomized, controlled trial, comparison of insulin detemir with NPH insulin, non‐hospitalized adults aged ≥18 years with either type 1 or type 2 diabetes, and study duration of ≥12 weeks. The following types of studies were excluded: non‐randomized controlled trials, studies of mixed cohorts of patients with type 1 or type 2 diabetes that did not report results separately, pharmacokinetic/pharmacodynamic studies, reviews, pooled or meta‐analyses or health‐economic analyses. Fourteen publications met the inclusion criteria. Nine studies in people with type 1 diabetes and three studies in people with type 2 diabetes, using insulin detemir in a basal–bolus regimen were included. Two studies were in people with type 2 diabetes using insulin detemir with oral antidiabetes medicines. In 14 studies of people with type 1 or type 2 diabetes, insulin detemir treatment provided similar or better glycaemic control, lower within‐subject variability, similar or lower frequency of hypoglycaemia and less weight gain when compared with NPH insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Self-citationHypoglycemia and cardiovascular risks
Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-s220 · Cited by 381 · cited 1×
“The morbidity of hypoglycaemia includes precipitation of acute cardiovascular events such as myocardial ischaemia and infarction, and the induction of cardiac arrhythmias [36], the risk of which is a particular consideration when treating people with type 2 diabetes who have a greater prevalence of coronary heart dise…”
BackgroundSelf-citationHermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004) · Diabetologia · doi:10.1007/s00125-004-1365-z · Cited by 365
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294 · cited 3×
“In six studies [13–17,20] that demonstrated similar glycaemic control between IDet and NPH insulin, two showed a significantly lower risk of hypoglycaemia with IDet [15,20], two reported a lower risk that was not significant for IDet [13,16] and two observed that the risk of hypoglycaemia was similar for the two insul…”
ResultKlein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251
Self-citationOng, K. L., Cheung, B. M. Y., Wong, L. Y. F., Wat, N. M. S., Tan, K. C. B., & Lam, K. S. L. (2008) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.10.007 · Cited by 232 · cited 1×
“0% (53 mmol/mol), or even lower, that are recommended by numerous professional organizations are seldom achieved by patients [5], which may be a consequence, at least in part, of the side effects of insulin.”
BackgroundRussell-Jones, D., Simpson, R., Hylleberg, B., Draeger, E., & Bolinder, J. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90072-0 · Cited by 194 · cited 5×
“In another study, IDet given once daily at bedtime showed less variability and fluctuation in glucose control, particularly at night, as measured using continuous glucose monitoring (figure 1) [13].”
MethodResultSelf-citationBartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159 · cited 8×
“001) in a 24-month basal–bolus trial of 495 patients [9].”
BackgroundResultInfluentialHallschmid, M., Jauch-Chara, K., Korn, O., Mölle, M., Rasch, B., Born, J., Schultes, B., & Kern, W. (2010) · Diabetes · doi:10.2337/db09-1493 · Cited by 61
Cited by
Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans
Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H., & Häring, H.-U. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 622
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Impaired insulin action in the human brain: causes and metabolic consequences
Heni, M., Kullmann, S., Preissl, H., Fritsche, A., & Häring, H.-U. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.173 · Cited by 245
Semlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80
Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194801 · Cited by 41
Metadata
- Authors
- Frier, B. M., Russell‐Jones, D., & Heise, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-05
- Volume
- 15
- Issue
- 11
- Pages
- 978-986
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2032055178
- Cited by
- 46
- References
- 10
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. https://app.cochat.ai/papers/10.1111/dom.12106
- The paper
- Frier, B. M., Russell‐Jones, D., & Heise, T. (2013). A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.